** Biotech firm Bio-Techne's TECH.O shares rise 4.8% to $76 premarket
** TECH beat Q2 earnings estimates, driven by growth in its protein sciences unit that develops biological compounds for research, diagnostics, and cell and gene therapy
** The protein sciences unit's sales rose 7% to $211.6 mln
** Company reports Q2 adj profit of 42 cents per share, above analysts' est of 39 cents - LSEG
** Posts Q2 sales of $297 mln, above analysts' est of $285.7 mln - LSEG
** TECH fell ~6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。